What is BIOCORRX INC NEW's earnings per share (EPS)?

BIOCORRX INC NEW (BICX) reported diluted earnings per share of -$0.19 for fiscal year 2025. This represents a 61.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

BIOCORRX INC NEW (BICX) Financials

BICX

FY2025 annual

Revenue $797K +10301.1% YoY

Net Income -$3.4M YoY not available

EPS (Diluted) -$0.19 +61.2% YoY

Operating Cash Flow -$2.3M -109.6% YoY

Market Cap $7.4M as of Oct 12, 2026

Price / Sales 9.3x on $797K revenue, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BICX SEC filings page.

BIOCORRX INC NEW (BICX) reported $797K in revenue for fiscal year 2025, up 10301.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BICX FY2025 2026-10-03

BioCorRx remains development-stage: 2025 revenue expanded, but R&D and overhead still outweighed sales, while liabilities dwarfed assets.

Revenue rebounded sharply in FY2025, yet operating margin was -606.0%, indicating sales volume had not begun absorbing the fixed operating base. R&D and SG&A totaled $5.6M against $797K revenue, making a development-stage cost structure rather than a scaled operating model with positive internal funding.

Assets rose from $386K in FY2024 to $2.1M in FY2025, but that expansion did not repair the capital structure. Liabilities were $13.7M against negative equity, so reported asset growth still leaves creditors’ claims far above the asset base. That combination limits the balance sheet’s ability to absorb operating losses.

Operating cash flow was -$2.3M in FY2025 while financing provided $2.3M, so reported cash needs were being met through financing rather than internally generated cash. The liquidity comparison was only 0.7 months of reported annual outflow, alongside a 0.1x current ratio, showing short-term obligations greatly exceeded current assets.

Financial Health Signals

Financial health score not available

BIOCORRX INC NEW does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-67.41

BIOCORRX INC NEW scores -67.41, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($7.4M) relative to total liabilities ($13.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/6

BIOCORRX INC NEW passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 3 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

BIOCORRX INC NEW reported a net loss of $3.4M while operations used $2.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

BIOCORRX INC NEW reported an operating loss of $4.8M against $224K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$88K

YoY-50.6%

QoQ-59.0%

BIOCORRX INC NEW generated $88K in revenue in Q2 2026. This represents a decrease of 50.6% from the same quarter a year earlier. Against the prior quarter it is down 59.0%.

EBITDA

-$1.5M

YoY-8.5%

QoQ-54.1%

BIOCORRX INC NEW's EBITDA was -$1.5M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 8.5% from the same quarter a year earlier. Against the prior quarter it is down 54.1%.

Net Income

-$965K

YoY+21.8%

QoQ-16.1%

BIOCORRX INC NEW reported -$965K in net income in Q2 2026. This represents an increase of 21.8% from the same quarter a year earlier. Against the prior quarter it is down 16.1%.

EPS (Diluted)

-$0.03

QoQ0.0%

BIOCORRX INC NEW earned -$0.03 per diluted share (EPS) in Q2 2026. It is unchanged from the prior quarter.

Cash & Balance Sheet

Cash & Debt

$21K

YoY-81.0%

QoQ-90.0%

5Y CAGR-50.3%

10Y CAGR-33.1%

BIOCORRX INC NEW held $21K in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

30M

QoQ+2.4%

5Y CAGR+35.0%

10Y CAGR-15.8%

BIOCORRX INC NEW had 30M shares outstanding in Q2 2026. Against the prior quarter it is up 2.4%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

-64.8%

YoY-164.8pp

QoQ-153.1pp

BIOCORRX INC NEW's gross margin was -64.8% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 164.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 153.1 percentage points.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$712K

YoY+140.0%

QoQ+102.2%

BIOCORRX INC NEW invested $712K in research and development in Q2 2026. This represents an increase of 140.0% from the same quarter a year earlier. Against the prior quarter it is up 102.2%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

BICX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BICX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	N/A	$797K+10301.1%	$8K-91.4%	$89K-58.3%	$214K+343.0%	$48K-60.6%	$123K-49.0%	$240K-36.2%	$377K-42.7%	$657K-6.3%	$702K-24.1%	$925K-21.0%	$1.2M+63.8%	$715K-17.6%	$868K+12.5%	$772K
Cost of Revenue	N/A	N/A	$2K-95.4%	$36K+89.9%	$19K+222.2%	$6K-93.9%	$96K+17.5%	$82K-52.2%	$171K-47.2%	$324K+84.5%	$175K+15.4%	$152K-31.2%	$221K+37.9%	$160K-60.2%	$402K+0.5%	$400K
Gross Profit	N/A	N/A	$6K-88.7%	$53K-72.7%	$195K+359.8%	$42K+58.9%	$27K-83.2%	$159K-22.9%	$206K-38.4%	$334K-36.6%	$526K-31.9%	$773K-18.7%	$950K+71.2%	$555K+19.1%	$466K+25.4%	$371K
R&D Expenses	N/A	$1.8M+19.3%	$1.5M+66.4%	$891K-38.9%	$1.5M-9.1%	$1.6M-62.4%	$4.3M+279.9%	$1.1M+641.3%	$152K-66.3%	$451K	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	$3.8M	N/A	N/A	$3.4M-8.9%	$3.7M+18.1%	$3.2M-30.6%	$4.6M	N/A	$2.7M+7.6%	$2.5M+19.7%	$2.1M-45.0%	$3.9M+32.5%	$2.9M+168.7%	$1.1M+52.2%	$714K
Operating Income	N/A	-$4.8M	N/A	N/A	N/A	N/A	-$7.5M-34.7%	-$5.6M	N/A	-$2.9M-32.5%	-$2.2M+57.4%	-$5.1M-67.7%	-$3.1M	N/A	N/A	N/A
EBITDA	N/A	-$4.8M	N/A	N/A	N/A	N/A	-$7.4M-34.0%	-$5.5M	N/A	-$2.9M-32.8%	-$2.2M+56.9%	-$5.0M-71.2%	-$2.9M	N/A	N/A	N/A
Interest Expense	N/A	$224K-71.2%	$777K+300.3%	$194K+28.5%	$151K+677.2%	$19K-96.2%	$511K-68.5%	$1.6M+182.8%	-$2.0M	N/A	$1.0M+177.9%	$377K+6.9%	$353K+13.7%	$310K	N/A	N/A
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0	N/A	N/A	N/A	N/A	N/A	$2K0.0%	$2K	N/A
Net Income	N/A	-$3.4M	N/A	N/A	N/A	N/A	-$3.5M+42.0%	-$6.0M	N/A	N/A	N/A	-$4.7M-49.2%	-$3.1M+18.5%	-$3.8M-333.3%	-$886K-116.6%	-$409K
EPS (Diluted)	—	-$0.19+61.2%	-$0.49	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	18M+76.7%	10M+288.0%	3M+86.3%	1M+37.2%	1M-7.5%	1M+0.5%	1M-53.3%	2M	2M-99.3%	250M+833.7%	27M+49.0%	18M+13.8%	16M-85.1%	106M+110.0%	51M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$88K-50.6%	$215K+59.0%	N/A	$635K	$178K+4306.4%	$135K+3626.5%	N/A	$0-100.0%
Cost of Revenue	$145K	$25K	N/A	N/A	$0	$0-100.0%	N/A	$0-100.0%
Gross Profit	-$57K-132.0%	$189K+40.4%	N/A	N/A	$178K+4306.4%	$135K+6807.3%	N/A	$0-100.0%
R&D Expenses	$712K+140.0%	$352K+117.6%	N/A	$1.0M+118.3%	$297K-44.7%	$162K-24.3%	N/A	$460K+60.3%
SG&A Expenses	$686K-43.9%	$775K-12.5%	N/A	$1.1M-4.0%	$1.2M+47.3%	$886K+18.1%	N/A	$1.2M+76.9%
Operating Income	-$1.5M-3.7%	-$956K-1.9%	N/A	-$1.9M-17.2%	-$1.4M-3.3%	-$938K+3.2%	N/A	-$1.7M-72.6%
EBITDA	-$1.5M-8.5%	-$945K-3.5%	N/A	-$1.9M-13.3%	-$1.3M+1.5%	-$913K+5.1%	N/A	-$1.7M-73.1%
Interest Expense	$30K-18.1%	$31K-64.5%	N/A	$30K-80.1%	$37K-88.5%	$87K-51.9%	N/A	$149K+304.0%
Income Tax	$0	$0	N/A	N/A	$0	$0	N/A	$0
Net Income	-$965K+21.8%	-$831K+1.2%	N/A	-$1.9M-28.9%	-$1.2M-1.3%	-$841K+32.0%	N/A	-$1.5M-71.5%
EPS (Diluted)	-$0.03	-$0.03	$0.05+162.5%	-$0.11	-$0.07	-$0.06	-$0.08	-$0.14
Diluted Shares (Avg)	29M	26M	N/A	18M	17M	15M+413.3%	N/A	11M

Not reported in any period shown, so not listed: EPS (Basic).

BICX Balance Sheet

BICX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$2.1M+456.4%	$386K-0.8%	$389K-49.3%	$767K-6.5%	$820K-55.1%	$1.8M-53.5%	$3.9M+526.1%	$628K+85.4%	$339K-28.0%	$470K-66.5%	$1.4M-65.6%	$4.1M-7.7%	$4.4M-12.9%	$5.1M+850.8%	$535K
Current Assets	$814K+590.3%	$118K-36.9%	$187K-41.0%	$317K+38.8%	$228K-76.6%	$975K-68.0%	$3.0M+854.3%	$319K+485.7%	$55K-46.0%	$101K-67.7%	$312K+46.3%	$213K-55.1%	$475K-57.0%	$1.1M	N/A
Cash & Equivalents	$139K+58.3%	$88K+35.0%	$65K-4.9%	$69K-20.1%	$86K-85.5%	$592K-77.6%	$2.6M+845.7%	$280K+2366.7%	$11K-87.7%	$92K-58.0%	$220K+314.3%	$53K-51.1%	$109K+1708.8%	$6K+262.2%	$2K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$143K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$253K	$0-100.0%	$740-97.9%	$35K+2258.5%	$2K+200.0%	$500-33.3%	$750-90.6%	$8K-73.3%	$30K	N/A	$3K-96.5%	$79K-73.8%	$299K+132.3%	-$926K-75.1%	-$529K
Long-Term Investments	$0	$0	$0-100.0%	$45K0.0%	$45K0.0%	$45K+6.2%	$42K+212.4%	$13K0.0%	$13K-23.9%	$18K+230.6%	$5K-91.5%	$63K+106.8%	$30K+1231.6%	$2K	$0
Goodwill	$563K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$13.7M+9.3%	$12.5M+22.5%	$10.2M+13.9%	$9.0M+15.3%	$7.8M+28.9%	$6.0M+20.9%	$5.0M-21.2%	$6.3M+49.7%	$4.2M-50.8%	$8.6M+83.5%	$4.7M+24.1%	$3.8M-10.1%	$4.2M+87.1%	$2.2M+176.0%	-$3.0M
Current Liabilities	$8.3M+1.2%	$8.2M+27.6%	$6.4M+19.9%	$5.4M+22.3%	$4.4M+43.7%	$3.1M+19.7%	$2.6M-58.4%	$6.1M+273.9%	$1.6M-33.2%	$2.5M-34.7%	$3.8M+93.8%	$1.9M+42.3%	$1.4M-31.3%	$2.0M+93.5%	$1.0M
Non-Current Liabilities	$5.4M+24.9%	$4.3M+13.7%	$3.8M+4.9%	$3.6M+6.2%	$3.4M+13.7%	$3.0M+22.3%	$2.4M+1076.4%	$208K-92.0%	$2.6M-57.8%	$6.1M+559.3%	$933K-49.3%	$1.8M-35.3%	$2.8M+974.0%	$265K+106.6%	-$4.0M
Long-Term Debt	N/A	N/A	N/A	$0-100.0%	$100K	N/A	N/A	N/A	N/A	N/A	$1.9M+141.1%	$770K-31.6%	$1.1M	N/A	N/A
Total Equity	-$11.2M+7.4%	-$12.1M-23.4%	-$9.8M-21.6%	-$8.1M-16.0%	-$7.0M-65.3%	-$4.2M-297.6%	-$1.1M+81.4%	-$5.7M-46.6%	-$3.9M+52.1%	-$8.1M-147.7%	-$3.3M-1171.8%	$306K+37.5%	$223K-92.1%	$2.8M-18.7%	$3.5M
Retained Earnings	-$86.6M-4.1%	-$83.2M-6.5%	-$78.1M-5.1%	-$74.3M-6.2%	-$70.0M-8.2%	-$64.7M-5.7%	-$61.2M-10.9%	-$55.2M-13.0%	-$48.8M-155.2%	-$19.1M-44.6%	-$13.2M-54.5%	-$8.6M-57.5%	-$5.4M-240.1%	-$1.6M-124.3%	-$713K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$1.9M-71.4%	$2.3M-65.8%	$2.1M+456.4%	$7.5M+1070.6%	$6.7M+1296.1%	$6.8M+2042.5%	$386K-0.8%	$644K+20.4%
Current Assets	$623K+18.2%	$1.0M+80.3%	$814K+590.3%	$1.5M+314.1%	$527K+206.7%	$566K+273.2%	$118K-36.9%	$353K+43.7%
Cash & Equivalents	$21K-81.0%	$212K+777.8%	$139K+58.3%	$288K+319553.3%	$112K+1237.4%	$24K-76.1%	$88K+35.0%	$90-99.9%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$44K-67.4%	$143K+7.4%	$143K	$155K	$134K	$134K	$0	N/A
Accounts Receivable	$68K+32.1%	$330K+195.0%	$253K	$194K	$51K	$112K	$0-100.0%	$0-100.0%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$563K-80.2%	$563K-80.2%	$563K	$2.8M	$2.8M	$2.8M	$0	N/A
Total Liabilities	$14.4M-27.0%	$13.9M-25.0%	$13.7M+9.3%	$20.3M+62.7%	$19.7M+71.6%	$18.6M+68.3%	$12.5M+22.5%	$12.5M+27.4%
Current Liabilities	$8.9M-39.2%	$8.5M-36.6%	$8.3M+1.2%	$15.0M+82.8%	$14.6M+99.0%	$13.4M+87.6%	$8.2M+27.6%	$8.2M+38.3%
Non-Current Liabilities	$5.5M+7.6%	$5.4M+5.1%	$5.4M+24.9%	$5.3M+23.7%	$5.1M+23.3%	$5.2M+32.7%	$4.3M+13.7%	$4.3M+10.5%
Total Equity	-$12.2M+3.2%	-$11.5M+0.9%	-$11.2M+7.4%	-$13.5M-14.0%	-$12.6M-14.8%	-$11.6M-7.6%	-$12.1M-23.4%	-$11.8M-29.6%
Retained Earnings	-$88.6M-3.8%	-$87.5M-4.1%	-$86.6M-4.1%	-$87.2M-6.3%	-$85.3M-5.9%	-$84.1M-5.9%	-$83.2M-6.5%	-$82.0M-6.4%

Not reported in any period shown, so not listed: Long-Term Debt.

BICX Cash Flow Statement

BICX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$2.4M	-$2.3M-109.6%	-$1.1M+40.8%	-$1.9M+9.2%	-$2.0M+42.3%	-$3.5M-64.4%	-$2.2M+26.7%	-$2.9M-60.9%	-$1.8M+28.1%	-$2.5M-27.1%	-$2.0M-4277.7%	$48K-71.5%	$168K+62.1%	$103K+111.2%	-$928K-622.6%	-$128K
Depreciation & Amortization	N/A	$44K+32.8%	$33K+23.6%	$27K-2.3%	$27K-57.3%	$64K-16.7%	$77K+162.7%	$29K+300.0%	$7K-78.3%	$34K+12.0%	$30K-75.8%	$125K-7.7%	$135K0.0%	$136K+6716.6%	$2K-9.3%	$2K
Stock-Based Compensation	N/A	$593K-51.4%	$1.2M+340.1%	$277K-21.8%	$355K+69.2%	$210K-41.0%	$355K-81.9%	$2.0M-30.0%	$2.8M+237.9%	$831K+42.7%	$582K+28.2%	$454K+51.4%	$300K+59.9%	$188K+403.9%	$37K	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	$0-100.0%	$2K	$0-100.0%	-$123K+1125.9%	$10K+236.7%	$3K-99.0%	$306K	N/A	$487-92.7%	$7K+712.8%	$820	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	-$2.0M+42.3%	-$3.5M-64.5%	-$2.2M+29.7%	-$3.1M-66.7%	-$1.8M+27.8%	-$2.5M-10.3%	-$2.3M	N/A	$167K+72.7%	$97K+110.4%	-$929K	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	$0+100.0%	-$50K-441.9%	-$9K+92.4%	-$122K-117.7%	-$56K-1783.7%	-$3K+99.1%	-$328K	N/A	-$33K+5.3%	-$35K+54.2%	-$76K-1395.8%	-$5K
Financing Cash Flow	$2.3M	$2.3M+110.0%	$1.1M-39.5%	$1.8M-8.6%	$2.0M-34.3%	$3.1M+2771.8%	$107K-98.0%	$5.4M+152.3%	$2.1M-10.9%	$2.4M+7.2%	$2.3M+1789.5%	$119K+162.6%	-$190K-662.3%	$34K-96.6%	$1.0M+687.5%	$128K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$440K-248.1%	-$433K+37.2%	-$848K-243.0%	-$634K-77.4%	-$126K+16.7%	-$690K-103.0%	-$247K+53.7%	-$358K-2.0%
Depreciation & Amortization	$10K-86.3%	$11K-54.9%	N/A	$72K+972.2%	$72K+972.0%	$25K+270.1%	N/A	$7K0.0%
Stock-Based Compensation	$0	$108K-28.4%	N/A	$16K-45.1%	$0-100.0%	$151K+212.2%	N/A	$29K+80.6%
Financing Cash Flow	$250K+16.5%	$506K-19.2%	$699K+108.7%	$810K+132.0%	$214K+262.1%	$626K+66.6%	$335K-24.3%	$349K+12.8%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

BICX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BICX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	N/A	78.3%+18.6pp	59.6%-31.5pp	91.1%+3.3pp	87.8%+66.1pp	21.8%-44.3pp	66.0%+11.4pp	54.6%+3.8pp	50.8%-24.2pp	75.0%-8.6pp	83.6%+2.4pp	81.1%+3.5pp	77.6%+24.0pp	53.6%+5.5pp	48.1%
Operating Margin	-606.0%	N/A	N/A	N/A	N/A	-6109.9%	-2314.7%	N/A	-439.8%	-310.9%	-553.5%	-260.7%	N/A	N/A	N/A
Net Margin	-431.5%	N/A	N/A	N/A	N/A	-2859.6%	-2517.4%	N/A	N/A	N/A	-504.6%	-267.1%	-536.9%	-102.0%	-53.0%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-1021.1%+701.8pp	-1722.9%-1691.7pp	-31.2%-19.5pp	-11.7%
Return on Assets	-160.2%	N/A	N/A	N/A	N/A	-191.9%-38.2pp	-153.8%	N/A	N/A	N/A	-332.0%-255.4pp	-76.6%+10.1pp	-86.7%-69.3pp	-17.4%+59.1pp	-76.5%
Current Ratio	0.10+0.1x	0.010.0x	0.030.0x	0.060.0x	0.05-0.3x	0.32-0.9x	1.19+1.1x	0.050.0x	0.030.0x	0.040.0x	0.080.0x	0.11-0.2x	0.35-0.2x	0.56	N/A
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	2.51-2.5x	5.05+4.3x	0.79	N/A
Asset Turnover	0.37+0.4x	0.02-0.2x	0.230.0x	0.28+0.2x	0.060.0x	0.070.0x	0.06-0.5x	0.60-1.3x	1.94+0.4x	1.49+0.8x	0.66+0.4x	0.29+0.1x	0.160.0x	0.17-1.3x	1.44
FCF Margin	N/A	N/A	N/A	-954.8%	-7332.8%	-1754.9%	-1273.5%	-487.4%	-387.0%	-328.5%	N/A	14.3%+0.7pp	13.5%	-107.0%	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	-64.8%-164.8pp	88.3%-11.7pp	N/A	N/A	100.0%0.0pp	100.0%+46.1pp	N/A	N/A
Operating Margin	-1666.0%	-445.6%	N/A	-306.3%	-793.3%	-695.3%	N/A	N/A
Net Margin	-1096.7%	-387.4%	N/A	-301.9%	-692.0%	-623.7%	N/A	N/A
Return on Assets	-50.6%-32.1pp	-35.8%-23.4pp	N/A	-25.5%+205.7pp	-18.5%+235.9pp	-12.4%+377.2pp	N/A	-231.1%-68.8pp
Current Ratio	0.070.0x	0.12+0.1x	0.10+0.1x	0.10+0.1x	0.040.0x	0.040.0x	0.010.0x	0.040.0x
Asset Turnover	0.050.0x	0.09+0.1x	N/A	0.08+0.1x	0.030.0x	0.020.0x	N/A	0.000.0x

Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Note: Shareholder equity is negative (-$11.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.10), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
BIOCORRX INC NEW BICX	FY2025	$797K	-$3.4M	N/A	$7.4M	—
SELECTIS HEALTH INC GBCS	FY2025	$41.4M	-$1.0M	-2.5%	$17.6M	—

Where BIOCORRX INC NEW Ranks

Frequently Asked Questions

What is BIOCORRX INC NEW's annual revenue?

BIOCORRX INC NEW (BICX) reported $797K in total revenue for fiscal year 2025. This represents a 10301.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is BIOCORRX INC NEW's revenue growing?

BIOCORRX INC NEW (BICX) revenue grew by 10301.1% year-over-year, from $8K to $797K in fiscal year 2025.

Is BIOCORRX INC NEW profitable?

No, BIOCORRX INC NEW (BICX) reported a net income of -$3.4M in fiscal year 2025.

What is BIOCORRX INC NEW's EBITDA?

BIOCORRX INC NEW (BICX) had EBITDA of -$4.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is BIOCORRX INC NEW's operating cash flow?

BIOCORRX INC NEW (BICX) recorded an outflow of $2.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are BIOCORRX INC NEW's total assets?

BIOCORRX INC NEW (BICX) had $2.1M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does BIOCORRX INC NEW spend on research and development?

BIOCORRX INC NEW (BICX) invested $1.8M in research and development during fiscal year 2025.

How many shares does BIOCORRX INC NEW have outstanding?

BIOCORRX INC NEW (BICX) had 26M shares outstanding as of fiscal year 2025.

What is BIOCORRX INC NEW's current ratio?

BIOCORRX INC NEW (BICX) had a current ratio of 0.10 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is BIOCORRX INC NEW's return on assets (ROA)?

BIOCORRX INC NEW (BICX) had a return on assets of -160.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is BIOCORRX INC NEW's P/E ratio?

BIOCORRX INC NEW (BICX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $7.4M as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is BIOCORRX INC NEW's price-to-sales ratio?

BIOCORRX INC NEW (BICX) trades at 9.3x sales, its market capitalization divided by revenue of $797K revenue, FY2025. The market capitalization is $7.4M as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does BIOCORRX INC NEW's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, BIOCORRX INC NEW (BICX) held $139K in cash, cash equivalents and investments, and reported an operating cash outflow of $2.3M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is BIOCORRX INC NEW's debt-to-equity ratio negative or not reported?

BIOCORRX INC NEW (BICX) has negative shareholder equity of -$11.2M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is BIOCORRX INC NEW's Altman Z-Score?

BIOCORRX INC NEW (BICX) has an Altman Z-Score of -67.41, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is BIOCORRX INC NEW's Piotroski F-Score?

BIOCORRX INC NEW (BICX) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are BIOCORRX INC NEW's earnings high quality?

BIOCORRX INC NEW (BICX) reported a net loss of $3.4M while operations used $2.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can BIOCORRX INC NEW cover its interest payments?

BIOCORRX INC NEW (BICX) reported an operating loss of $4.8M against $224K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.